1,3-Diazaspiro[5.5]undecane-2,4-dione | 1340492-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,3-Diazaspiro[5.5]undecane-2,4-dione
• CAS: 1340492-22-9
• 化学式: C₉H₁₄N₂O₂
• 分子量: 182.22
• InChiKey: OFWUXAJZSPLBDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] ETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015128307A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of formula I, wherein Y is N or C-R1'; R1' is hydrogen or F; R1 is hydrogen, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; or R2 forms together with R4 a 6 membered heterocyclic ring containing -CH2-CH2-O-CH2- or -CH2-CH2-NR-C(O)-; R is hydrogen, lower alkyl, phenyl or benzyl; R3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; R4' is hydrogen, lower alkyl or lower alkoxyalkyl; R4 is hydrogen, lower alkyl, phenyl optionally substituted by halogen or lower alkoxy, or is cycloalkyl, or is pyridinyl optionally substituted by halogen, lower alkyl, lower alkoxy or =0, or is pyrimidinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is 1 -lower alkyl-pyridinyl, or is pyrazinyl, or is pyridazinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is l-methylpyrrolo[2,3-b]pyridine-5-yl, or is 6-imidazo[l,2- b]pyridazin-6-yl; or R4 forms together with R4' a 4, 5 or 6 membered heterocyclic ring containing -(CH2)5-, -CH2-CH2-O-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-O-CH2-CH2- or CH2-CH2-CH2-O-CH2; R5 and R5' are hydrogen or lower alkyl; or R4 forms together with R5 a saturated 5- membered ring containing -CH2-CH2-CH2-; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及以下式I的化合物，其中Y为N或C-R1'；R1'为氢或F；R1为氢、卤素或经卤素取代的较低烷基；R2为氢或较低烷基；或R2与R4一起形成一个含有-CH2- -O- -或- - -NR-C(O)-的6元杂环环；R为氢、较低烷基、苯基或苄基；R3为苯基或吡啶基，其中吡啶基中的N原子可能在不同位置；R4'为氢、较低烷基或较低烷氧基烷基；R4为氢、较低烷基、苯基（可选择地经卤素或较低烷氧基取代）、环烷基、或吡啶基（可选择地经卤素、较低烷基、较低烷氧基或=0取代）、或嘧啶基（可选择地经较低烷基、较低烷氧基或=0取代）、或1-较低烷基-吡啶基，或吡嗪基，或吡啶嗪（可选择地经较低烷基、较低烷氧基或=0取代），或1-甲基吡咯并[2,3-b]吡啶-5-基，或6-咪唑并[1,2-b]吡嗪-6-基；或R4与R4'一起形成含有-( )5-、- - -O- - -、- - - -、- - - - -、- -O- - -或 - - -O- -的4、5或6元杂环环；R5和R5'为氢或较低烷基；或R4与R5一起形成一个饱和的含有- - - -的5元环；或制药学上可接受的盐或酸加成盐，或消旋混合物，或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑、恶心、强迫性障碍、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• ETHYNYL DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3110802A1

  公开（公告）日：2017-01-04